Dr. Li was appointed as the chairman of the Board, an executive Director and the CEO on January 20, 2017. He is mainly responsible for the formulation of the corporate development strategies and direction for our Group as well as overall day-to-day management of our business and operations. Dr. Li Xiaoyi also holds directorship at each subsidiary of our Group since its establishment.

Dr. Li has over 25 years of experience in pharmaceutical research and development as well as management and strategic planning for pharmaceutical companies. Dr. Li founded Lee’s Pharm in 1994 and has been the chief technical officer since then. Dr. Li was appointed as an executive director and the chief executive officer of Lee’s Pharm in September 2003, where he is responsible for the overall operations and management and research and development of Lee’s Pharm. Dr. Li will resign as the chief technical officer, the chief executive officer and executive director of Lee’s Pharm before the Listing.

In addition to his roles in Lee’s Pharm, Dr. Li also has multiple experience in the management and strategic planning for many other pharmaceutical institutions. Since 2014, he has been serving as the vice president of Hong Kong Biotechnology Organization, mainly responsible for developing the biotech industry in Hong Kong. Since March 2016, he has been serving as the president of Guangzhou Pharmaceutical Association* (广州药学会), an academic and non-profit social organization formed by pharmaceutical researchers in Guangzhou, where he is mainly responsible for providing industrial insights for developing the pharmaceutical industry in Guangzhou. Dr. Li is also a member of the review committee of Innovation and Technology Fund of Hong Kong Government, a fund supported by the government of Hong Kong to promote and facilitate technology companies.

Dr. Li obtained his Ph.D. in pharmacology from the medicine college of the University of Illinois in the United States in May 1992.

Dr. Li has earned multiple awards and esteemed recognitions. He has been an adjunct professor at the Hong Kong University of Science and Technology since November 2013 and an honorary fellow since June 2016. In August 2018, he was awarded the leading innovation talent (广州创新领军人才) by the Guangzhou government. In January 2018, Dr. Li was appointed as a member of the People’s Political Consultative Conference of Anhui Province in the PRC, and was honored with the 16th World Outstanding Chinese Award (世界杰出华人奖) by the World Chinese Business Investment Foundation (世界华商投资基金会) in August 2018.

Mr. Dai joined our Group in June 2016 and was appointed as an executive Director on October 23, 2020. He is mainly responsible for overseeing research and development and daily operation of our Group.

As a licensed pharmacist, Mr. Dai has over 13 years of extensive experience in preclinical studies, clinical research and registration of new drugs. Prior to joining our Group, Mr. Dai had worked in Lee's Pharm since July 2007, where he was responsible for various new drug development programs and succeeded in bringing the programs to the clinical trial stage, and was further promoted to senior director of the research and development centre in February 2016. Mr. Dai obtained both his bachelor's degree in horticulture and his master's degree in biochemistry from Anhui Agricultural University (安徽农业大学) in Anhui Province, China, in July 2003 and June 2007, respectively.

Ms.Zhang was appointed as a non-executive Director on February 5, 2021 and is primarily responsible for providing guidance and advice on the corporate and business strategies of our Group. Ms. Zhang was nominated as a Director by Panacea Venture Healthcare Fund I, L.P., a Pre-IPO Investor.

Ms. Zhang has over 10 years of management and investment experience in healthcare industry. From January 2009 to April 2012, Ms. Zhang worked as a manager of business development at Hutchison MediPharma Limited, which is a subsidiary of Hutchison China MediTech Limited, a company whose share are traded on the NASDAQ (ticker symbol: HCM), where she was responsible for drug out-licensing and project management. From July 2014 to December 2015, Ms. Zhang worked as an associate manager at Zimmer Biomet Holdings, Inc., a company whose shares are traded on the New York Stock Exchange (ticker symbol: ZBH), where she was responsible for management of strategic initiatives. In January 2016, Ms. Zhang joined and is now a partner of Kleiner Perkins Caufield & Byers China (凯鹏华盈中国基金) and focusing on the firm’s life science practice and portfolio management. Ms. Zhang joined Panacea Venture since January 2018, a venture capital focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide, where she involves in the firm’s life science practice, portfolio management and fund raising.

Ms. Zhang graduated from the University of Texas at Austin, the United States with a bachelor of science degree in biochemistry in December 2006. She obtained a master degree in biotechnology from the Graduate School of Arts and Sciences of Columbia University, the United States in October 2008, and a master of business administration degree from the Fuqua School of Business of Duke University, the United States, in May 2014.

Ms. Leelalertsuphakun was appointed as a non-executive Director on February 20, 2017 and is primarily responsible for providing guidance and advice on the corporate and business strategies of our Group.

Ms. Leelalertsuphakun is an entrepreneur and had established and run several companies since the 1990s. Prior to joining our Group, she joined Lee's Pharm in April 1997. She has been appointed as an executive director and managing director of Lee's Pharm since December 2001, and further as the chief marketing and sales officer of Lee’s Pharm since September 2003, where she was responsible for the sales and marketing activities of Lee's Pharm.

Ms. Cai was appointed as a non-executive Director on October 23, 2020 and is mainly responsible for providing guidance and advice on the corporate and business strategies.Ms. Cai was nominated as a Director by TPG Asia VII SF Pte. Ltd., a Pre-IPO Investor.

From 2007 through 2008, Ms. Cai worked as a research analyst at Credit Suisse AG (New York), where she was responsible for equity research for large cap of medical supplies and devices companies. From March 2009 to July 2011, Ms. Cai worked as an investment associate at HAO Capital (Haotian Jinsheng Investment Management (Beijing) Limited), focusing on growth stage healthcare investments. Ms. Cai joined TPG Capital in August 2011 and is latest serving as a managing director of TPG Capital, a leading global alternative asset firm, responsible for TPG Capital's healthcare investments in Greater China.

Ms. Cai obtained her bachelor’s degree in biomedical engineering and economics from Yale University in Connecticut, the United States in May 2007.

Mr. Wong was appointed as an independent non-executive Director on April 1, 2021 and is primarily responsible for supervising and providing independent judgment to our Board.

Mr. Wong has 36 years of experience in accounting, finance, investment management and advisory. From July 1985 to September 1996, Mr. Wong worked successively as an auditor in an international audit firm for four years and chief financial officer of a Hong Kong listed company for seven years. Subsequently in 1997, Mr. Wong co-founded Silk Road International Capital Limited (formerly known as Legend Capital Partners, Inc.), a licensed corporation under the SFO, and led the company as an executive director and the responsible officer for 23 years. Since 2020, Mr. Wong has been serving as the managing partner and the responsible officer of Hermitage Capital HK Limited, a licensed corporation under the SFO.

Mr. Wong obtained his master's degree in Executive Business Administration from The Chinese University of Hong Kong in December 1996. Mr. Wong has been a fellow member of the Hong Kong Institute of Certified Public Accountants since July 1995, a fellow member of the Chartered Association of Certified Accountants since July 1992, a fellow member of the Institute of Chartered Accountants in England and Wales since March 2015, a fellow member of the Institute of Chartered Secretaries and Administrators of the United Kingdom since June 1995, a fellow member of the Hong Kong Institute of Directors since April 2002, a member of the American Institute of Certified Public Accountants since February 1991, a chartered member of Chartered Institute for Securities and Investment of the United Kingdom since March 2011.

Prof. Lo was appointed as an independent nonexecutive Director on April 1, 2021 and is primarily responsible for supervising and providing independent judgment to our Board.

Prof. Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Since July 2019, he has been serving as the Chairman of GT Healthcare Capital Partners, a private investment partnership specializing in healthcare investments. From July 2007 to June 2009, he was a member of the Hong Kong Government Research Grants Council. He was the Chairman of the Advisory Council on Food and Environmental Hygiene of the Hong Kong Government from April 2015 to March 2021 and he has been the president for HK Bio-Med Innotech Association. He also serves as the honorary chairman of the Hong Kong Biotechnology Organisation. Since February 2019, he has been serving as the partner of Hongsen Investment Management Ltd, an investment company focusing on growing biotech companies.

In recognition of his leadership in the community and dedication to his field, Prof. Lo has received many awards. In 2000, he was the first to be bestowed with the title of honorary fellow by the Hong Kong University of Science and Technology for his role in establishing Hong Kong's biotechnology industry. He was awarded China's "Top Ten Financial and Intelligent Persons" in 2007 in recognition of his outstanding contribution to economic development and business innovation in China. He was honored with the World Outstanding Chinese Award (世界杰出华人奖) by the World Chinese Business Investment Foundation (世界华商投资基金会) in June 2008, the Pericles International Prize 2019 by the Alcmaeon International Academy in June 2019, and the HKSAR Bronze Bauhinia Star by the government of Hong Kong in October 2020.

Mr. Liew Fui Kiang, aged 58, was appointed as an independent non-executive Director on June 6, 2022 and is primarily responsible for supervising and providing independent judgment to our Board.

Mr. Liew is currently an independent non-executive director of (i) Shandong Gold Mining Co., Ltd., a company dually listed on the Stock Exchange (stock code: 1787) and Shanghai Stock Exchange (stock code: 600547); (ii) China Apex Group Limited, a company listed on the Stock Exchange (stock code:02011); (iii) Zhengye lnternational Holdings Company Limited, a company listed on the Stock Exchange(stock code: 3363); and (iv) Zhongchang lnternational Holdings Group Limited, a company listed on the Stock Exchange (stock code: 859).

Mr. Liew currently serves as an independent member of the board of supervisors for Ping An insurance(Group) Company of China Limited, a company dually listed on the Stock Exchange (stock code: 2318)and Shanghai Stock Exchange (stock code: 601318), a Fortune Global 500 corporation.

Mr. Liew previously served as (i) an independent director of Baoshan lron & Steel Company Limited (宝山钢铁股份有限公司),a company listed on Shanghai Stock Exchange (stock code: 600019), a Fortune Global 500 corporation; and (ii) the chairman of the board of directors and an executive director of PacRay lnternational Holdings Limited, a company listed on the Stock Exchange (stock code: 1010)

Mr. Liew is a fellow of the Hong Kong Institute of Directors, a solicitor of England and Wales, and a solicitor of Hong Kong. He graduated from the University of Leeds in the United Kingdom with a Bachelor of Laws as a Tetley & Lupton scholar, and he graduated from the Hull University Business School in the United Kingdom with a master of business administration.